SAN DIEGO, May 31, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (“Apricus Bio”) (Nasdaq:APRI) (http://www.apricusbio.com) announced today that the Israeli Patent Office has allowed and granted the Company a patent entitled, “Topical Compositions for Prostaglandin E1 Delivery.” The patent, for the use of Prostaglandin E1 (otherwise known as “PGE1" or “alprostadil”) in combination with the Company’s proprietary NexACT® technology for Raynaud’s Phenomenon covering its drug candidate RayVa™, among other potential product candidates, will provide coverage to May 13, 2019 and expands the protection for Apricus Bio’s alprostadil-based products in Israel to eight granted patents.
